PARM1

Across TCGA pan-cancer cohorts, PARM1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PARM1 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PARM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARM1 expression acts as an unfavorable survival marker.

SKCM, BLCA, and PRAD are the cancer types where PARM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.430	0.794	<.001	21	view →
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PARM1–SKCM (OS)

Open the SKCM breakdown →